Cardiovascular Risk Estimation and Eligibility for Statins in Primary Prevention Comparing Different Strategies

被引:12
|
作者
Nanchen, David [1 ,2 ]
Chiolero, Arnaud [2 ]
Cornuz, Jacques [1 ]
Marques-Vidal, Pedro-Manuel [2 ]
Firmann, Mathieu [3 ]
Mooser, Vincent [4 ]
Paccaud, Fred [2 ]
Waeber, Gerard [3 ]
Vollenweider, Peter [3 ]
Rodondi, Nicolas [1 ]
机构
[1] Univ Lausanne, Univ Hosp Ctr, Dept Ambulatory Care & Community Med, Lausanne, Switzerland
[2] Univ Lausanne, Univ Hosp Ctr, Inst Social & Prevent Med, Lausanne, Switzerland
[3] Univ Lausanne, Univ Hosp Ctr, Dept Med, Lausanne, Switzerland
[4] GlaxoSmithKline, Div Genet, King Of Prussia, PA USA
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2009年 / 103卷 / 08期
关键词
CORONARY-HEART-DISEASE; EUROPEAN GUIDELINES; FRAMINGHAM; POPULATION; THERAPY; SCORE; EPIDEMIOLOGY; PARTICIPANTS; METAANALYSIS; MORTALITY;
D O I
10.1016/j.amjcard.2008.12.042
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recommendations for statin use for primary prevention of coronary heart disease (CHID) are based on estimation of the 10-year CHD risk. It is unclear which risk algorithm and guidelines should be used in European populations. Using data from a population-based study in Switzerland, we first assessed 10-year CHD risk and eligibility for statins in 5,683 women and men 35 to 75 years of age without cardiovascular disease by comparing recommendations by the European Society of Cardiology without and with extrapolation of risk to age 60 years, the International Atherosclerosis Society, and the US Adult Treatment Panel III. The proportions of participants classified as high-risk for CHD were 12.5% (15.4% with extrapolation), 3.0%, and 5.8%, respectively. Proportions of participants eligible for statins were 9.2% (11.6% with extrapolation), 13.7%, and 16.7%, respectively. Assuming full compliance to each guideline, expected relative decreases in CHD deaths in Switzerland over a 10-year period would be 16.4% (17.5% with extrapolation), 18.7%, and 19.3%, respectively; the corresponding numbers needed to treat to prevent 1 CHD death would be 285 (340 with extrapolation), 380, and 440, respectively. In conclusion, the proportion of subjects classified as high risk for CHD varied over a fivefold range across recommendations. Following the International Atherosclerosis Society and the Adult Treatment Panel III recommendations might prevent more CHD deaths at the cost of higher numbers needed to treat compared with European Society of Cardiology guidelines. (C) 2009 Elsevier Inc. All rights reserved. (Am J Cardiol 2009;103:1089-1095)
引用
收藏
页码:1089 / 1095
页数:7
相关论文
共 50 条
  • [41] Cost-Effectiveness of Statins for Primary Cardiovascular Prevention in Chronic Kidney Disease
    Erickson, Kevin F.
    Japa, Sohan
    Owens, Douglas K.
    Chertow, Glenn M.
    Garber, Alan M.
    Goldhaber-Fiebert, Jeremy D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (12) : 1250 - 1258
  • [42] Effect of Statins for Primary Prevention of Cardiovascular Disease According to the Fatty Liver Index
    Yoo, Joonsang
    Jeon, Jimin
    Baik, Minyoul
    Kim, Jinkwon
    JOURNAL OF EPIDEMIOLOGY AND GLOBAL HEALTH, 2024, 14 (03) : 710 - 719
  • [43] Statins for Primary Prevention of Cardiovascular Disease Review of Evidence and Recommendations for Clinical Practice
    Kazi, Dhruv S.
    Penko, Joanne M.
    Bibbins-Domingo, Kirsten
    MEDICAL CLINICS OF NORTH AMERICA, 2017, 101 (04) : 689 - +
  • [44] Global Cardiovascular Risk Management in Primary Prevention
    Volpe, Massimo
    Tocci, Giuliano
    CURRENT VASCULAR PHARMACOLOGY, 2012, 10 (06) : 709 - 711
  • [45] Cardiovascular risk stratification in overweight or obese patients in primary prevention. Implications for use of statins
    Masson, Walter
    Lobo, Martin
    Huerin, Melina
    Molinero, Graciela
    Manente, Diego
    Pangaro, Mario
    Vitagliano, Laura
    Zylbersztejn, Horacio
    ENDOCRINOLOGIA Y NUTRICION, 2015, 62 (02): : 83 - 90
  • [46] Do statins benefit low-risk population for primary prevention of atherosclerotic cardiovascular disease: A retrospective cohort study
    Ryou, In Sun
    Kim, Ju Young
    Park, Hwa Yeon
    Oh, Sohee
    Kim, Sehun
    Kim, Hwa Jung
    FRONTIERS IN MEDICINE, 2022, 9
  • [47] Statins and Cardiovascular Primary Prevention in CKD: A Meta-Analysis
    Major, Rupert W.
    Cheung, Chee Kay
    Gray, Laura J.
    Brunskill, Nigel J.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2015, 10 (05): : 732 - 739
  • [48] Statins and All-Cause Mortality in High-Risk Primary Prevention of Patients With Cardiovascular Risk Factors
    Brugts, Jasper Jan
    Deckers, Jaap W.
    ARCHIVES OF INTERNAL MEDICINE, 2010, 170 (22) : 2041 - 2041
  • [49] Comparison Shopping: Guidelines for Statins for Primary Prevention of Cardiovascular Disease
    Mancini, G. B. John
    ANNALS OF INTERNAL MEDICINE, 2018, 168 (02) : 145 - 146
  • [50] Primary Prevention for Cardiovascular Diseases: Can Statins Replace Aspirin?
    Hadi, Muhammad Abdul
    Ming, Long Chiau
    Awaisu, Ahmed
    MEDICAL PRINCIPLES AND PRACTICE, 2011, 20 (06) : 584 - 584